All patients
age >= 55 yr age >= 60 yr age >= 65 yr autoimmune disease corticosteroids: no corticosteroids: yes critical disease invasive ventilation no oxygen needed non invasive oxygen omicron variant BA.1 (B.1.1.529) severe disease solid organ transplant recipients subjects at risk
anti-inflammatoty and immuno-therapy in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results Balcells, 2020 4.22 [0.33; 53.77]
4.22 [0.33 ; 53.77 ] Balcells, 2020 1 0% 58 NA not evaluable deathsdetailed results Balcells, 2020 3.26 [0.62; 17.12]
3.26 [0.62 ; 17.12 ] Balcells, 2020 1 0% 58 NA not evaluable deaths (time to event analysis only)detailed results Balcells, 2020 3.26 [0.62; 17.12]
3.26 [0.62 ; 17.12 ] Balcells, 2020 1 0% 58 NA not evaluable clinical deteriorationdetailed results Balcells, 2020 1.46 [0.44; 4.81]
1.46 [0.44 ; 4.81 ] Balcells, 2020 1 0% 58 NA not evaluable clinical improvementdetailed results Balcells, 2020 0.91 [0.52; 1.60]
0.91 [0.52 ; 1.60 ] Balcells, 2020 1 0% 58 NA not evaluable clinical improvement (time to event analysis only)detailed results Balcells, 2020 0.91 [0.52; 1.60]
0.91 [0.52 ; 1.60 ] Balcells, 2020 1 0% 58 NA not evaluable death or ventilationdetailed results Balcells, 2020 0.67 [0.14; 3.26]
0.67 [0.14 ; 3.26 ] Balcells, 2020 1 0% 58 NA not evaluable mechanical ventilationdetailed results Balcells, 2020 2.98 [0.41; 21.61]
2.98 [0.41 ; 21.61 ] Balcells, 2020 1 0% NA not evaluable viral clearance detailed results Balcells, 2020 2.66 [0.69; 10.20]
2.66 [0.69 ; 10.20 ] Balcells, 2020 1 0% 47 NA not evaluable viral clearance by day 7detailed results Balcells, 2020 2.66 [0.69; 10.20]
2.66 [0.69 ; 10.20 ] Balcells, 2020 1 0% 47 NA not evaluable serious adverse eventsdetailed results Balcells, 2020 4.54 [0.20; 105.23]
4.54 [0.20 ; 105.23 ] Balcells, 2020 1 0% 58 NA not evaluable 0.5 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-05 07:42 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 95,94,90,91
- treatments: 546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525
- roots T: 290